sFlt-1/PlGF ratio for the predictive diagnosis of preeclampsia: budget impact analysis from the public healthcare perspective in Portugal
Autor(a) principal: | |
---|---|
Data de Publicação: | 2019 |
Outros Autores: | , , , , |
Tipo de documento: | Artigo |
Idioma: | eng |
Título da fonte: | Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
Texto Completo: | http://scielo.pt/scielo.php?script=sci_arttext&pid=S1646-58302019000200003 |
Resumo: | Overview and Aims: The last decade brought relevant insights into the pathophysiology of preeclampsia (PE), namely the role of the circulating levels of placental growth factor (PlGF) and soluble Fms-like tyrosine kinase-1 (sFlt-1). The purpose of this study is to estimate the financial impact of introducing the sFlt-1/PlGF ratio for the evaluation of women with suspicion of PE in the Portuguese National Healthcare System (SNS). Study Design: budget impact study evaluating short-term costs associated with the introduction of the sFlt-1/PlGF ratio from the SNS payer's perspective. The time horizon for the study is 1 year. Population: The target population consists of women presenting to the healthcare system with signs or symptoms suggestive of preeclampsia (estimated in 8500 subjects). Methods: A decision-tree model was used to estimate the budget impact of the introduction of the sFlt-1/PlGF ratio in the SNS. The model compares the management costs in the current clinical practice (no test scenario) vs. current diagnostic procedures plus the sFlt-1/PlGF ratio (test scenario). Clinical inputs have been derived primarily from literature review and, where data was unavailable, expert opinion. Resources and unit costs have been obtained from Portugal-specific sources. Results: In the current standard practice (no test), total costs were estimated to be e9 863 264 (e1160 per patient), with unnecessary admissions representing about e3,5 million. Total costs in the test scenario sum up to e9 781 194 (e1150 per patient), representing a cost saving to the system of e82 070 (e10 per patient), mainly due to a reduction of false positives and related unnecessary hospitalizations of women not developing PE. Conclusions: There is favorable economic evidence about the introduction of the sFlt- 1/PlGF ratio in the SNS. The generated savings appear to offset the costs related to the test. |
id |
RCAP_64988e77d57159eaeb165f491d992016 |
---|---|
oai_identifier_str |
oai:scielo:S1646-58302019000200003 |
network_acronym_str |
RCAP |
network_name_str |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
repository_id_str |
7160 |
spelling |
sFlt-1/PlGF ratio for the predictive diagnosis of preeclampsia: budget impact analysis from the public healthcare perspective in PortugalPreeclampsiaPregnancyBiomarkersCosts and Cost AnalysisOverview and Aims: The last decade brought relevant insights into the pathophysiology of preeclampsia (PE), namely the role of the circulating levels of placental growth factor (PlGF) and soluble Fms-like tyrosine kinase-1 (sFlt-1). The purpose of this study is to estimate the financial impact of introducing the sFlt-1/PlGF ratio for the evaluation of women with suspicion of PE in the Portuguese National Healthcare System (SNS). Study Design: budget impact study evaluating short-term costs associated with the introduction of the sFlt-1/PlGF ratio from the SNS payer's perspective. The time horizon for the study is 1 year. Population: The target population consists of women presenting to the healthcare system with signs or symptoms suggestive of preeclampsia (estimated in 8500 subjects). Methods: A decision-tree model was used to estimate the budget impact of the introduction of the sFlt-1/PlGF ratio in the SNS. The model compares the management costs in the current clinical practice (no test scenario) vs. current diagnostic procedures plus the sFlt-1/PlGF ratio (test scenario). Clinical inputs have been derived primarily from literature review and, where data was unavailable, expert opinion. Resources and unit costs have been obtained from Portugal-specific sources. Results: In the current standard practice (no test), total costs were estimated to be e9 863 264 (e1160 per patient), with unnecessary admissions representing about e3,5 million. Total costs in the test scenario sum up to e9 781 194 (e1150 per patient), representing a cost saving to the system of e82 070 (e10 per patient), mainly due to a reduction of false positives and related unnecessary hospitalizations of women not developing PE. Conclusions: There is favorable economic evidence about the introduction of the sFlt- 1/PlGF ratio in the SNS. The generated savings appear to offset the costs related to the test.Euromédice, Edições Médicas Lda.2019-06-01info:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articletext/htmlhttp://scielo.pt/scielo.php?script=sci_arttext&pid=S1646-58302019000200003Acta Obstétrica e Ginecológica Portuguesa v.13 n.2 2019reponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãoinstacron:RCAAPenghttp://scielo.pt/scielo.php?script=sci_arttext&pid=S1646-58302019000200003Campos,AnaMachado,Ana PaulaMartins,HelenaPais,Maria São JoséÉrsek,KatalinLopes,Nelsoninfo:eu-repo/semantics/openAccess2024-02-06T17:21:45Zoai:scielo:S1646-58302019000200003Portal AgregadorONGhttps://www.rcaap.pt/oai/openaireopendoar:71602024-03-20T02:28:40.680768Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãofalse |
dc.title.none.fl_str_mv |
sFlt-1/PlGF ratio for the predictive diagnosis of preeclampsia: budget impact analysis from the public healthcare perspective in Portugal |
title |
sFlt-1/PlGF ratio for the predictive diagnosis of preeclampsia: budget impact analysis from the public healthcare perspective in Portugal |
spellingShingle |
sFlt-1/PlGF ratio for the predictive diagnosis of preeclampsia: budget impact analysis from the public healthcare perspective in Portugal Campos,Ana Preeclampsia Pregnancy Biomarkers Costs and Cost Analysis |
title_short |
sFlt-1/PlGF ratio for the predictive diagnosis of preeclampsia: budget impact analysis from the public healthcare perspective in Portugal |
title_full |
sFlt-1/PlGF ratio for the predictive diagnosis of preeclampsia: budget impact analysis from the public healthcare perspective in Portugal |
title_fullStr |
sFlt-1/PlGF ratio for the predictive diagnosis of preeclampsia: budget impact analysis from the public healthcare perspective in Portugal |
title_full_unstemmed |
sFlt-1/PlGF ratio for the predictive diagnosis of preeclampsia: budget impact analysis from the public healthcare perspective in Portugal |
title_sort |
sFlt-1/PlGF ratio for the predictive diagnosis of preeclampsia: budget impact analysis from the public healthcare perspective in Portugal |
author |
Campos,Ana |
author_facet |
Campos,Ana Machado,Ana Paula Martins,Helena Pais,Maria São José Érsek,Katalin Lopes,Nelson |
author_role |
author |
author2 |
Machado,Ana Paula Martins,Helena Pais,Maria São José Érsek,Katalin Lopes,Nelson |
author2_role |
author author author author author |
dc.contributor.author.fl_str_mv |
Campos,Ana Machado,Ana Paula Martins,Helena Pais,Maria São José Érsek,Katalin Lopes,Nelson |
dc.subject.por.fl_str_mv |
Preeclampsia Pregnancy Biomarkers Costs and Cost Analysis |
topic |
Preeclampsia Pregnancy Biomarkers Costs and Cost Analysis |
description |
Overview and Aims: The last decade brought relevant insights into the pathophysiology of preeclampsia (PE), namely the role of the circulating levels of placental growth factor (PlGF) and soluble Fms-like tyrosine kinase-1 (sFlt-1). The purpose of this study is to estimate the financial impact of introducing the sFlt-1/PlGF ratio for the evaluation of women with suspicion of PE in the Portuguese National Healthcare System (SNS). Study Design: budget impact study evaluating short-term costs associated with the introduction of the sFlt-1/PlGF ratio from the SNS payer's perspective. The time horizon for the study is 1 year. Population: The target population consists of women presenting to the healthcare system with signs or symptoms suggestive of preeclampsia (estimated in 8500 subjects). Methods: A decision-tree model was used to estimate the budget impact of the introduction of the sFlt-1/PlGF ratio in the SNS. The model compares the management costs in the current clinical practice (no test scenario) vs. current diagnostic procedures plus the sFlt-1/PlGF ratio (test scenario). Clinical inputs have been derived primarily from literature review and, where data was unavailable, expert opinion. Resources and unit costs have been obtained from Portugal-specific sources. Results: In the current standard practice (no test), total costs were estimated to be e9 863 264 (e1160 per patient), with unnecessary admissions representing about e3,5 million. Total costs in the test scenario sum up to e9 781 194 (e1150 per patient), representing a cost saving to the system of e82 070 (e10 per patient), mainly due to a reduction of false positives and related unnecessary hospitalizations of women not developing PE. Conclusions: There is favorable economic evidence about the introduction of the sFlt- 1/PlGF ratio in the SNS. The generated savings appear to offset the costs related to the test. |
publishDate |
2019 |
dc.date.none.fl_str_mv |
2019-06-01 |
dc.type.status.fl_str_mv |
info:eu-repo/semantics/publishedVersion |
dc.type.driver.fl_str_mv |
info:eu-repo/semantics/article |
format |
article |
status_str |
publishedVersion |
dc.identifier.uri.fl_str_mv |
http://scielo.pt/scielo.php?script=sci_arttext&pid=S1646-58302019000200003 |
url |
http://scielo.pt/scielo.php?script=sci_arttext&pid=S1646-58302019000200003 |
dc.language.iso.fl_str_mv |
eng |
language |
eng |
dc.relation.none.fl_str_mv |
http://scielo.pt/scielo.php?script=sci_arttext&pid=S1646-58302019000200003 |
dc.rights.driver.fl_str_mv |
info:eu-repo/semantics/openAccess |
eu_rights_str_mv |
openAccess |
dc.format.none.fl_str_mv |
text/html |
dc.publisher.none.fl_str_mv |
Euromédice, Edições Médicas Lda. |
publisher.none.fl_str_mv |
Euromédice, Edições Médicas Lda. |
dc.source.none.fl_str_mv |
Acta Obstétrica e Ginecológica Portuguesa v.13 n.2 2019 reponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação instacron:RCAAP |
instname_str |
Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação |
instacron_str |
RCAAP |
institution |
RCAAP |
reponame_str |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
collection |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
repository.name.fl_str_mv |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação |
repository.mail.fl_str_mv |
|
_version_ |
1799137356386664448 |